Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

about

Anti-quorum Sensing Activities of Selected Coral Symbiotic Bacterial Extracts From the South China Sea.Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms

P2860

Q55112668-3E709896-510C-46C2-B9A3-CDF49A856619 Q57041845-2011C37F-ED67-46AC-9B69-478301F8EC01

P2860

Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

Item

http://www.wikidata.org/entity/Q40540795

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical potential of engineer ...... ainst drug resistant biofilms.

@en

type

Item

label

Clinical potential of engineer ...... ainst drug resistant biofilms.

@en

prefLabel

Clinical potential of engineer ...... ainst drug resistant biofilms.

@en

P1476

Clinical potential of engineer ...... ainst drug resistant biofilms.

@en

P2093

Jennifer M Bomberger

http://www.w3.org/2001/XMLSchema#string

Ronald C Montelaro

http://www.w3.org/2001/XMLSchema#string

P2860

Induced Bacterial Cross-Resistance toward Host Antimicrobial Peptides: A Worrying Phenomenon

The potential impact of coinfection on antimicrobial chemotherapy and drug resistance

LAMP: A Database Linking Antimicrobial Peptides

Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei.

Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections.

Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Binding interactions of bacterial lipopolysaccharide and the cationic amphiphilic peptides polymyxin B and WLBU2.

The polymicrobial nature of biofilm infection.

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens.

Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids.

P304

989-991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14787210.2016.1236687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey A. Melvin

P577

2016-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27626708

http://www.w3.org/2001/XMLSchema#string

P921

Biofilm

P932

5177990

http://www.w3.org/2001/XMLSchema#string

Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

about

P2860

P2860

Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932